Clinical trials: Pneumococcal Disease, active
Pneumococcal Disease
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and…
- Trial name
- NCT07573462
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Where
- 78 sites in United States, Argentina and 8 more
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and…
- Trial name
- NCT07660198
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Where
- 77 sites in United States, Finland and 2 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant
The purpose of this study is to learn about the safety of the 20-valent pneumococcal conjugate vaccine (20vPnC) among adults, children, and infants, as well as the immunogenicity of 20vPnC among infants and children under 2 years…
- Trial name
- NCT07023081
- Testing
- 20vPnC, 13vPnC
- Where
- 2 sites in China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and…
- Trial name
- NCT07629440
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Where
- 130 sites in United States, Japan and 1 more
- Volunteers
- 3,230 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs in infants when compared to the pneumococcal vaccines that are currently in…
- Trial name
- NCT06524414
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15)
- Where
- 67 sites in United States, Puerto Rico
- Volunteers
- 605 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults
The purpose of this study is to provide safety data and demonstrate lot consistency with the PG4 vaccine by evaluating the immunogenicity of 3 different lots of this vaccine.
- Trial name
- NCT07794748
- Testing
- PG4 Multivalent Vaccine, 20 Valent Pneumococcal Conjugate Vaccine (20vPnC)
- Where
- 37 sites in United States
- Volunteers
- 4,670 people, healthy volunteers welcome
- Sponsor
- Pfizer
Severe Acute Malnutrition in Childhood, Pneumococcal Disease
Opportunistic Pneumococcal Immunisation Trial in MALnutrition
The goal of the OPTIMAL clinical trial is to learn if a dose of a pneumococcal conjugate vaccine (PCV) generates a good immune response in young children who are in hospital with severe acute malnutrition.
- Conditions
- Severe Acute Malnutrition in Childhood, Pneumococcal Disease, Pneumococcal Vaccines, Pneumococcal Infection
- Trial name
- OPTIMAL (NCT06817421)
- Testing
- Pneumococcal conjugate vaccine, Typhoid conjugate vaccine
- Where
- Timor-Leste
- Volunteers
- 214 people
- Sponsor
- Nick Fancourt
Pneumococcal Infectious Diseases
A Lot-to-Lot Consistency Clinical Trial of PCV13
A Phase IIIb clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 to 5 years.
- Trial name
- NCT07832500
- Testing
- Sinovac PCV13 lot 1, Sinovac PCV13 lot 2, Sinovac PCV13 lot 3
- Where
- China
- Volunteers
- 1,125 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Vaccine, Pneumococcal Disease
Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria.
- Trial name
- Group 33/PCVs (NCT07135453)
- Testing
- Pneumococcal Vaccine
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Pneumococcal Diseases
A Study to Evaluate 20vPnC in Healthy Chinese Infants
The purpose of this study is to evaluate a study vaccine called 20-valent pneumococcal conjugate vaccine (20vPnC). The study will assess whether the study vaccine is safe to use in healthy infants.
- Trial name
- NCT07754539
- Testing
- 20vPnC, 13vPnC
- Where
- 4 sites in China
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infectious Diseases
Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)
A Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in infants aged approximately 2 months (42 to 89 days).
- Trial name
- NCT07593924
- Testing
- Sinovac PCV13, Prevenar 13™
- Where
- Philippines
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Pneumococcal Disease Prevention
A Study on the Immunization Schedule for the 13-Valent Pneumococcal Polysaccharide-Conjugate Vaccine in Healthy Infants
To compare the immunogenicity of the domestically produced PCV13 vaccine in healthy 2-month-old infants following administration via the 2+1 and 3+1 schedules, with the primary endpoint being the seroprevalence of specific IgG…
- Trial name
- NCT07591181
- Testing
- the domestically produced 13-valent Pneumococcal Polysaccharide Conjugate vaccine
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Beijing Center for Disease Control and Prevention
Pneumococcal Disease
A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months
The purpose of this study is to learn about the safety of 20-valent Pneumococcal Conjugate Vaccine (PREVENAR 20) under actual clinical practice in Japan.
- Trial name
- NCT06622109
- Testing
- 20-valent Pneumococcal Conjugate Vaccine
- Where
- Japan
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Pneumococcal Infectious Disease
Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
A Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday).
- Trial name
- NCT06617715
- Testing
- Sinovac PCV13, Prevnar®
- Where
- China
- Volunteers
- 3,080 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Infants Aged 2-23 Months
A Phase 1b clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 42 days)-23 months.
- Trial name
- NCT06800261
- Testing
- Sinovac PCV24, Prevnar®
- Where
- 2 sites in China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years
A Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years.
- Trial name
- NCT07300644
- Testing
- Sinovac PCV24, Prevnar®
- Where
- 3 sites in China
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Pneumococcal Disease, Invasive, Pneumococcal Disease
Serum Collection Study for Assay Development
The study will collect serum from 12 participants vaccinated with Gamma-PN to assist with assay development and validation
- Trial name
- NCT07205289
- Testing
- Gamma-PN
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GPN Vaccines
Pneumococcal Disease, Invasive
Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants
Phase 2 trial to evaluate safety and immunogenicity of Inventprise's (IVT) 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in Healthy Infants
- Trial name
- NCT06790290
- Testing
- Formulation B, Formulation C, Formulation D
- Where
- 3 sites in Philippines
- Volunteers
- 421 people, healthy volunteers welcome
- Sponsor
- Inventprise Inc.
Pneumococcal Diseases
A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60
This Phase I, randomized, double-blind, parallel-controlled study is to be conducted in healthy adults aged 60 and above. Participants will be randomly assigned in a 1:1 ratio to receive either 26-valent Pneumococcal Conjugate…
- Trial name
- NCT06970756
- Testing
- 26-valent Pneumococcal Conjugate Vaccine, 13-valent Pneumococcal Conjugate Vaccine
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Pneumococcal Disease, Pneumococcal Carriage
Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15
Streptococcus pneumoniae (pneumococcus) is a bacterium that causes just under four million serious infections every year. It is normal for pneumococcus bacteria to live in the noses of healthy adults and children as part of the…
- Trial name
- RATIONALE-15 (NCT06731374)
- Testing
- PCV15, Streptococcus pneumoniae serotype 3
- Where
- 2 sites in United Kingdom
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University of Oxford